Results 151 to 160 of about 7,229 (203)
Some of the next articles are maybe not open access.
Drugs, 2012
Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. The randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials in antiretroviral-naive adult patients with HIV-1 infection compared rilpivirine ...
Mark Sanford
exaly +3 more sources
Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. The randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials in antiretroviral-naive adult patients with HIV-1 infection compared rilpivirine ...
Mark Sanford
exaly +3 more sources
Chirality, 2018
AbstractNuclear magnetic resonance (NMR) technique has been used to find the property of atropisomerism in Rilpivirine hydrochloride by variable temperature analysis and various 2D techniques. Both the Rilpivirine hydrochloride (E‐isomer) and Impurity‐A (Z‐isomer) isomers have been differentiated and confirmed by NMR and ultraviolet techniques ...
Senthilkumar Natarajan
exaly +3 more sources
AbstractNuclear magnetic resonance (NMR) technique has been used to find the property of atropisomerism in Rilpivirine hydrochloride by variable temperature analysis and various 2D techniques. Both the Rilpivirine hydrochloride (E‐isomer) and Impurity‐A (Z‐isomer) isomers have been differentiated and confirmed by NMR and ultraviolet techniques ...
Senthilkumar Natarajan
exaly +3 more sources
Journal of Antimicrobial Chemotherapy, 2021 International audienceAbstract Background Multivariable baseline factor analysis across cabotegravir\mkern1mu+\mkern1murilpivirine clinical trials showed that HIV-1 subtypes A6/A1 and the presence of rilpivirine resistance-associated mutations (RAMs ...
Sidonie Lambert-Niclot +2 more
exaly +2 more sources
Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study. [PDF]
Clinical Infectious DiseasesBackground: Obesity is increasingly prevalent among people with human immunodeficiency virus (HIV, PWH). Obesity can reduce drug exposure; however, limited data are available for long-acting (LA) antiretrovirals.
Catia Marzolini +2 more
exaly +2 more sources
Dolutegravir–rilpivirine coformulation
Current Opinion in HIV and AIDS, 2018With prolonged life expectancy in HIV-positive patients on combination antiretroviral therapy, the quest for reducing lifelong drug exposure and minimizing or avoiding the toxicities of combination antiretroviral therapy while maintaining viral suppression has emerged when coformulations of antiretroviral agents with improved convenience, and better ...
Hsin-Yun, Sun +2 more
openaire +2 more sources
Cabotegravir and rilpivirine for the treatment of HIV
Expert Review of Anti-infective Therapy, 2020Introduction: Antiretroviral treatment (ART) has led to improved control of HIV infection, giving the opportunity of exploring therapeutic alternatives as new long-acting (LA) regimens, that might improve the quality of life of people living with HIV (PLWH).Areas covered: This article overviews the pharmacokinetic and pharmacodynamic properties of LA ...
David Rial-Crestelo +2 more
openaire +2 more sources
European Journal of Clinical Pharmacology, 2018 Purpose Rilpivirine, prescribed for the treatment of HIV infection, presents an important inter-individual pharmacokineticvariability. We aimed to determine population pharmacokinetic parameters of rilpivirine in adult HIV-infected patients andquantify ...
catherine DHIVER +2 more
exaly +1 more source